Application of extracorporeal membrane oxygenation in the perioperative period of lung transplantation
Q4 Medicine
C. Ma, J. Bai, M. Wu, X. Du
{"title":"Application of extracorporeal membrane oxygenation in the perioperative period of lung transplantation","authors":"C. Ma, J. Bai, M. Wu, X. Du","doi":"10.14188/j.1671-8852.2021.6011","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the application of extracorporeal membrane oxygenation (ECMO) in the perioperative period of lung transplantation, and summarize the experience. Methods: The clinical data of 19 patients receiving lung transplantation operation in Renmin Hospital of Wuhan University from December 2016 to December 2020 were retrospectively analyzed. Patients were divided into groups according to whether ECMO support was used, and their clinical data were compared. Results: Among the 19 patients, there were 5 cases of chronic obstructive pulmonary disease, 3 cases of bronchiectasis, 4 cases of pneumoconiosis, 4 cases of idiopathic pulmonary fibrosis, 1 case of connective tissue disease interstitial pulmonary fibrosis, 1 case of Kartagener syndrome, and 1 case of COVID-19 with advanced pulmonary fibrosis. Among the 10 patients in the non-ECMO group, 1 died during the operation, 1 died after abandoning treatment, and 1 was discharged after abandoning treatment. There were 9 patients in the ECMO group, 2 patients received ECMO bridged treatment before surgery, and the remaining 7 patients received ECMO adjuvant treatment after anesthesia. In the ECMO group, 1 patient died, 1 patient was discharged after abandoning treatment, and the rest patients were all improved and discharged after successful weaning of ECMO. The two groups only differed in the way of preoperative respiratory support (P=0.033). There were no significant differences in gender, age, preoperative assessment, surgical process, length of hospital stay, ICU stay, postoperative multi-drug resistant organism infection, and outcome. Conclusion: ECMO is an important auxiliary tool during the perioperative period of lung transplantation. The use of ECMO did not increase the risk of postoperative infection with multidrug-resistant bacteria, nor did it lead to an increase in mortality. In the other hand, the choice of preoperative respiratory support method has reference for perioperative patients whether to use ECMO. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.","PeriodicalId":35402,"journal":{"name":"武汉大学学报(医学版)","volume":"42 1","pages":"558-563"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"武汉大学学报(医学版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14188/j.1671-8852.2021.6011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To investigate the application of extracorporeal membrane oxygenation (ECMO) in the perioperative period of lung transplantation, and summarize the experience. Methods: The clinical data of 19 patients receiving lung transplantation operation in Renmin Hospital of Wuhan University from December 2016 to December 2020 were retrospectively analyzed. Patients were divided into groups according to whether ECMO support was used, and their clinical data were compared. Results: Among the 19 patients, there were 5 cases of chronic obstructive pulmonary disease, 3 cases of bronchiectasis, 4 cases of pneumoconiosis, 4 cases of idiopathic pulmonary fibrosis, 1 case of connective tissue disease interstitial pulmonary fibrosis, 1 case of Kartagener syndrome, and 1 case of COVID-19 with advanced pulmonary fibrosis. Among the 10 patients in the non-ECMO group, 1 died during the operation, 1 died after abandoning treatment, and 1 was discharged after abandoning treatment. There were 9 patients in the ECMO group, 2 patients received ECMO bridged treatment before surgery, and the remaining 7 patients received ECMO adjuvant treatment after anesthesia. In the ECMO group, 1 patient died, 1 patient was discharged after abandoning treatment, and the rest patients were all improved and discharged after successful weaning of ECMO. The two groups only differed in the way of preoperative respiratory support (P=0.033). There were no significant differences in gender, age, preoperative assessment, surgical process, length of hospital stay, ICU stay, postoperative multi-drug resistant organism infection, and outcome. Conclusion: ECMO is an important auxiliary tool during the perioperative period of lung transplantation. The use of ECMO did not increase the risk of postoperative infection with multidrug-resistant bacteria, nor did it lead to an increase in mortality. In the other hand, the choice of preoperative respiratory support method has reference for perioperative patients whether to use ECMO. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.
体外膜氧合在肺移植围手术期的应用
目的:探讨体外膜氧合(ECMO)在肺移植围手术期的应用,总结经验。方法:回顾性分析2016年12月至2020年12月武汉大学人民医院19例肺移植手术患者的临床资料。根据是否使用ECMO支持将患者分为两组,比较两组患者的临床资料。结果:19例患者中,慢性阻塞性肺疾病5例,支气管扩张3例,尘肺病4例,特发性肺纤维化4例,结缔组织病间质性肺纤维化1例,Kartagener综合征1例,COVID-19合并晚期肺纤维化1例。非ecmo组10例患者,术中死亡1例,放弃治疗后死亡1例,放弃治疗后出院1例。ECMO组9例,2例术前接受ECMO桥接治疗,其余7例麻醉后接受ECMO辅助治疗。ECMO组1例死亡,1例放弃治疗出院,其余患者均好转,成功脱机后出院。两组仅在术前呼吸支持方式上有差异(P=0.033)。性别、年龄、术前评估、手术过程、住院时间、ICU住院时间、术后多药耐药菌感染和结局无显著差异。结论:ECMO是肺移植围手术期重要的辅助工具。ECMO的使用没有增加术后多药耐药菌感染的风险,也没有导致死亡率的增加。另一方面,术前呼吸支持方式的选择对围手术期患者是否采用ECMO有参考意义。©2021,武汉大学医学杂志编辑委员会。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。